MedTrace Logo

Endoscopy for Assessment of Mucosal Healing in IBD

NCT01417702 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 232

Last updated 2020-12-14

No results posted yet for this study

Summary

Inflammatory bowel disease (IBD) encompasses two major forms of chronic intestinal disorders, Crohn's disease and ulcerative colitis (UC). Diagnosis is based on several macroscopic and histologic features including patterns of inflammation, crypt abscesses and granulomas. i-Scan use an endoscopic image from the video processor and reconstruct virtual images in real time, resulting in an improved contrast of the capillary patterns and enhancement of the mucosal surface (so called virtual chromoendoscopy).

The main objective of this study is to determine endoscopic features of mucosal healing in patients with IBD and to compare these features to clinical and histological data in order to establish a new endoscopic classification of mucosal healing and to evaluate mucosal healing as a parameter of remission and relapse.

Conditions

Interventions

DEVICE

High-definition white light endoscopy and i-Scan

Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Helmut Neumann, Professor · Department of Medicine I, University of Erlangen-Nuremberg, Germany

  • Markus F. Neurath, Professor · Department of Medicine I, University of Erlangen-Nuremberg, Germany

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-05-31
Completion
2014-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01417702 on ClinicalTrials.gov